Resveratrol analog (Z)-3,5,4′-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization

International Journal of Cancer

Volumn 107, Issue 2, 2003, Pages 189-196

  Schneider, Yann ^a   Chabert, Philippe ^b   Stutzmann, Jeanne ^c   Coelho, David ^a   Fougerousse, André ^b   Gossé, Francine ^a   Launay, Jean François ^c   Brouillard, Raymond ^b   Raul, Francis ^a  

^a IRCAD   (France)

^b CNRS   (France)

^c INSERM   (France)

Author keywords

Caco 2 cells; Cell cycle; Colchicine; Colon cancer; Polyamine; Tubulin

Indexed keywords

3,5,4' TRIMETHOXYSTILBENE; ADENOSYLMETHIONINE DECARBOXYLASE; ANTIMITOTIC AGENT; COLCHICINE; DRUG ANALOG; ORNITHINE DECARBOXYLASE; POLYAMINE; PUTRESCINE; RESVERATROL; SPERMIDINE; TUBULIN; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BINDING SITE; CANCER INHIBITION; CELL CYCLE; CELL STRAIN CACO 2; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG CONFORMATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BINDING SITES; CACO-2 CELLS; CELL CYCLE; CELL DIVISION; COLCHICINE; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GOUT SUPPRESSANTS; HUMANS; MICROTUBULES; MITOSIS; ORNITHINE DECARBOXYLASE; POLYAMINES; POLYMERS; STILBENES; TUBULIN; TUBULIN MODULATORS; VINBLASTINE;

EID: 0141857816     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11344     Document Type: Article

References (43)

1. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? and gone? Clin Biochem 1997;30:91-113.
2. Langcake P, Pryce RJ. The production of resveratrol by Vitis vinifera and the other members of the Vitaceae as a response to infection or injury. Physiol Plant Pathol 1976;9:77-86.
3. Schoeppner A, Kindl H. Stilbene synthase (pinosylvine synthase) and its induction by ultraviolet light. FEBS Lett 1979;108:349-53.
4. Siemann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am J Enol Vittic 1992;43:49-52.
5. Fauconneau B, Waffo-Teguo P, Huguet F, Barrier L, Decendit A, Merillon JM. Comparative study of radical scavenger and antioxydant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sci 1997;61:2103-10.
6. Chanvitayapongs S, Draczynska-Lusiak B, Sun AY. Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Neuroreport 1997;8:1499-1502.
7. Pace-Asciak CR, Hanh S, Diamandis EP, Soleas G, Goldberg DM. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995;235:207-19.
8. Bertelli AA, Giovannini L, Giannessi D, Migliori M, Bernini W, Fregoni M, Bertelli A. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 1995;17:1-3.
9. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, Fong HHS, Farnsworth NR, Kinghorn AD, Menta RG, Moon RC, Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-20.
10. Subbaramaiah K, Chung WL, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM, Dannenberg AJ. Resveratrol inhibit cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998;273:21875-82.
11. Fontcave M, Lepoivre M, Elleingand E, Gerez C, Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett 1997421:277-9.
12. Schneider Y, Duranton B, Gossé F, Schleiffer R, Seiler N, Raul F. Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer 2001;39:102-7.
13. Langcake P, Cornford CA, Pryce RJ. Identification of pterostilbene as a phytoalexin from Vitis vinifera leaves. Phytochemistry 1979;18:1025-7.
14. Pont V, Pezet R. Relation between the chemical structure and the biological activity of hydroxystilbenes against Botrytis cinerea. J Phytopathol 1990;130:1-8.
15. Kandaswami C, Perkins E, Soloniuk DS, Drezewiecki G, Middleton E Jr. Antiproliferative effects of citrus flavonoids on a human squamous cell carcinoma in vitro. Cancer Lett 1991;56:147-52.
16. Schneider Y, Vincent F, Duranton B, Badolo L, Gossé F, Bergmann C, Seiler N, Raul F, Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 2000;158:85-91.
17. Bachelor FW, Loman AA, Snowdon LR. Synthesis of pinosylvin and related heartwood stilbene. Can J Chem 1970;48:1554-7.
18. Malan E, Swinn, C, Ferreira D, Hall AJ. Metabolites from Chlorophora excelsa possible intermediate in the biogenesis of pentasubstituted stilbene. Phytochemistry 1983:27:2309-12.
19. Skehan P Storen, R Scudiero D Monks A, McMahon J, Vistica D, Warren JT, Boekesch H, Kenney S, Boyd MR. New colorimetric cytotoxic assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
20. Nicoletti I, Migliorati G, Pagliacci MC, Grignai F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
21. Richman RA, Underwood LE, Van JJW, Boina JJ. Synergic effect of cortisol and growth hormone on hepatic ornithine decarboxylase activity. Proc Soc Exp Biol Med 1971;138:880-4.
22. Persson L, Holm I, Heby O. Translation regulation of ornithine decarboxylase by polyamines. FEBS Lett 1986;295:175-8.
23. Seiler N, Knödgen B. High performance liquid chromatographic procedure for the simultaneous determination of the natural polyamines and their monoacetyl derivatives. J Chromatogr 1980;221:227-35.
24. Verhoven B, Schlegel RA, Williamson P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal on apoptotic T lymphocytes. J Exp Med 1995;182:1597-601.
25. Williams JR, Little JB, Shipley WU. Association of mammalian cell death with a specific endonucleolytic degradation of DNA. Nature 1974;252:744-55.
26. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol 1982;243:C212-21.
27. Heby O, Sarna GP, Marton LJ, Omine M, Perry S, Russell DH. Polyamine contents of AKR leukemic cells in relation to the cell cycle. Cancer Res 1973;33:2959-64.
28. Cushmann M, Nagarathnam D, Gopal D, Chakraborti AK, Lin CM, Hamel E. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerisation. J Med Chem 1991;34:2579-88.
29. Olmsted JB, Borisy GG. Characterization of microtubule assembly in porcine brain extracts by viscometry. Biochemistry 1973;12:4282-9.
30. Feldmann G, Maurice M. Microtubules, microfilaments and cellular secretion Biol Gastroenterol 1975;8:269-74.
31. Jordan MA., Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998;18:259-96,
32. Tahir SK, Han EKH, Credo B, Jae HS, Pietenpol JA, Scatena CD, Wu-Wong JR, Frost D, Sham H, Rosenberg SH, Ng SC. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res 2001;61:5480-5.
33. Anderson PJ, Bardocz S, Campos R, Brown DL. The effect of polyamines on tubulin assembly. Biochem Biophys Res Commun 1985;132:147-54.
34. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung, YS, Longo, DL. Involvement of microtubules in the regula tion of Bcl-2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 1998;18:3509-17.
35. Sorger PK, Dobles M, Toumebize R, Hyman AA. Coupling cell division and cell death to microtubule dynamics. Curr Opin Cell Biol 1997;9:807-14.
36. Fan W. Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 1999;57:1215-21.
37. Gartel AL, Serfas MS, Gartel M, Goufman E, Wu GS, El-Deiry WS, Tyner AL. p21 (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line. Exp Cell Res 1996;227:171-81.
38. Galmarini CM, Falette N, Tabone E, Levrat C, Britten R, Voorzanger-Rousselot N, Roesch-Gateau O, Vanier-Viornery A, Puisieux A, Dumontet C. Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity. Br J Cancer 2001;85:902-8.
39. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L. Taxol induction of p21WAF1 and p53 requires c-raf-1, Cancer Res 1995;55:4623-6.
40. Van Bree C, Savonije JH, Franken NA, Haveman J, Bakker PJ. The effect of p53-function on the sensitivity to paclitaxel with or without hyperthermia in human colorectal carcinoma cells. Int J Oncol 2000;16:739-44.
41. Tsuiki H, Nitta M, Tada M, Inagaki M, Ushio Y, Saya H. Mechanism of hyperploid cell formation induced by microtubule inhibiting drug in glioma cell lines. Oncogene 2001;20:420-9.
42. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in Hela cells by low concentrations of paclitaxel (taxel) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:812-25.
43. Sherwood SW, Sheridan JP, Schimke RT. Induction of apoptosis by the anti-tubulin drug colcemid, relationhip of mitotic checkpoint control to the induction of apoptosis in HeLa S3 cells. Exp Cell Res. 1994;215:373-9.